Search results
Results from the WOW.Com Content Network
Xanomeline/trospium chloride, sold under the brand name Cobenfy, is a fixed-dose combination medication used for the treatment of schizophrenia. [1] It contains xanomeline , a muscarinic agonist ; and trospium chloride , a muscarinic antagonist . [ 1 ]
William Blair analysts expect $2.5 billion in U.S. sales for Cobenfy by 2030. Bristol said it expects to make the drug available to patients by late October at a list price of $1,850 a month or ...
The KarXT approval comes after decades of no significant treatment advancements for schizophrenia patients. About 3.7 million, or 1.8%, of adults in the U.S. have a lifetime history of ...
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb ...
Xanomeline/trospium, sold under the brand name Cobenfy, is an approved combination drug used in the treatment of schizophrenia. [ 6 ] [ 7 ] Trospium chloride is a peripherally selective non-selective muscarinic antagonist to quell peripheral muscarinic agonist-dependent side effects.
In 2024, the United States FDA approved the drug KarXT (Cobenfy), which is a combination drug that combines xanomeline (a preferentially acting M1/M4 muscarinic acetylcholine receptor agonist) with trospium (a peripherally-restricted pan-mAChR antagonist for use in schizophrenia.
The medicine works in an entirely different way from existing treatments.
This is a list of investigational antipsychotics, or antipsychotics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.